Nurix Therapeutics, Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines. Its 8-K reports furnish quarterly and annual financial results, corporate presentations, clinical-program updates for bexobrutideg and pipeline programs, and other material events tied to research, development and financing activity.
The company’s SEC disclosures also cover its common stock listed on the Nasdaq Global Market, shelf registration and at-the-market equity distribution arrangements, underwritten equity offerings, and use-of-proceeds language tied to clinical development and research programs. Proxy and governance filings document board composition, director appointments, compensation programs, committee assignments and annual stockholder meeting matters.
Nurix Therapeutics, Inc. (NRIX) said collaboration partner Sanofi S.A. notified it of a decision to discontinue the Phase 1 first-in-human clinical trial of SAR448272, an oral STAT6 degrader, and terminate the program. Nurix does not expect future development, regulatory or commercial milestone payments or royalties under the Sanofi collaboration with respect to SAR448272. Nurix remains eligible for milestone payments and royalties on other previously announced licensed programs that Sanofi may, at its discretion, develop further into clinical candidates. The company cited the risk that Sanofi may not advance those programs and that collaborators may discontinue or delay partnered-program development.
Nurix Therapeutics, Inc. Chief Financial Officer Hans van Houte reported the vesting and conversion of 10,182 restricted stock units into common stock on October 30, 2026. He also sold 2,834 shares at a weighted average price of $26.2791 per share to cover tax withholding. Nurix's equity incentive plans required the sale, which was not discretionary.
Nurix Therapeutics, Inc. Chief Legal Officer Christine Ring reported vesting 10,182 restricted stock units and acquiring the corresponding common shares on October 30, 2026. She also reported selling 3,957 shares at a weighted average price of $26.2791 per share.
Nurix Therapeutics Chief Scientific Officer Gwenn Hansen reported an option exercise and stock sales on November 2, 2026, plus RSU vesting and a tax-withholding sale on October 30, 2026. She exercised options for 1,452 shares at $1.86 per share and sold 1,452 shares at $26.80 per share under a previously adopted Rule 10b5-1 plan. On October 30, 3,750, 2,859 and 3,573 RSUs vested into common shares; she sold 3,957 shares at a weighted average price of $26.2791 per share to cover tax withholding, as required by the issuer's equity plans.
Nurix Therapeutics, Inc. officer Christine Ring reported a proposed sale of 10,602 common shares, with an aggregate market value of $284,133.60 and an approximate sale date of November 2, 2026.
The notice also lists four sales under a Rule 10b5-1 plan during the preceding three months: 5,787 shares on August 3, 2026; 10,802 shares on August 3, 2026; 5,787 shares on September 2, 2026; and 5,786 shares on October 2, 2026.
Nurix Therapeutics, Inc. Chief Scientific Officer Gwenn Hansen exercised options covering 1,452 shares at an exercise price of $1.86 per share on October 15, 2026, acquired 1,452 common shares, and sold those shares at $25.00 per share. The transactions were effected pursuant to a Rule 10b5-1 trading plan previously adopted by Hansen. Following the exercise, her reported option position was 59,406 shares.
Nurix Therapeutics, Inc. director Julia Gregory reported a proposed sale of 22,583 common shares, with an aggregate market value of $528,528.02. The notice lists October 14, 2026 as the approximate sale date and Morgan Stanley Smith Barney LLC as broker, with the sale on Nasdaq. The shares are listed as acquired from the issuer through a stock option exercise for cash.
Nurix Therapeutics, Inc. (NRIX) director Julia P. Gregory exercised a director stock option for 22,583 shares of common stock on October 14, 2026, at $1.86 per share, then sold 22,583 shares at a weighted average price of $23.4038. Sale prices ranged from $23.34 to $23.62. The director stock option had a reported post-exercise balance of 0 shares. No Rule 10b5-1 plan is reported.
Nurix Therapeutics, Inc. (NRIX) reported revenue of $673.1 million for the three months ended August 31, 2026, versus $7.9 million a year earlier, and net income of $549.8 million versus a net loss of $86.4 million. Of the quarter’s revenue, $653.2 million was license revenue recognized from the Roche collaboration’s $700.0 million upfront payment. For the nine months, revenue was $688.4 million and net income was $373.1 million.
Under the bexobrutideg (NX-5948) agreement, Nurix and Roche will co-develop and co-commercialize the drug in the United States. Global development costs are shared 40% by Nurix and 60% by Roche, and U.S. net profits and losses are shared equally. Nurix is eligible for up to approximately $1.6 billion in additional payments and tiered royalties on sales outside the United States. As of August 31, 2026, cash, cash equivalents and marketable securities totaled $1.1 billion; management said these funds were sufficient for operating activities for at least 12 months following issuance. Nurix expects additional losses until it can generate significant product sales and says it will need substantial additional funding.
Nurix Therapeutics, Inc. reported fiscal third-quarter 2026 revenue of $673.1 million, compared with $7.9 million a year earlier, primarily reflecting $653.2 million of Roche collaboration license revenue and a $10 million Sanofi milestone. Net income was $549.8 million, versus a net loss of $86.4 million. Cash, cash equivalents and marketable securities totaled $1.1 billion as of August 31, 2026, following receipt of Roche’s $700 million upfront payment; Nurix said its cash runway extends into the second half of 2029.
Nurix and Roche began the Phase 3 DAYBreak CLL-306 trial of bexobrutideg versus pirtobrutinib, designed for approximately 620 patients. The companies share development costs 40%/60%, share U.S. profits and losses equally, and Nurix is eligible for tiered ex-U.S. royalties. Nurix also reported Phase 1a results of median progression-free survival of 22.1 months and an 83.0% objective response rate, advanced NX-1607 into expansion cohorts, and discontinued further clinical development of NX-2127.